Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: BIOLOGICAL: AE37 Peptide vaccine|BIOLOGICAL: Pembrolizumab
Sponsor: NuGenerex Immuno-Oncology
Collaborators: Merck Sharp & Dohme LLC|NSABP Foundation Inc